CTCBIO Inc (060590) - Net Assets

Latest as of September 2025: ₩71.75 Billion KRW ≈ $48.62 Million USD

Based on the latest financial reports, CTCBIO Inc (060590) has net assets worth ₩71.75 Billion KRW (≈ $48.62 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩149.18 Billion ≈ $101.10 Million USD) and total liabilities (₩77.43 Billion ≈ $52.47 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore CTCBIO Inc total assets for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩71.75 Billion
% of Total Assets 48.1%
Annual Growth Rate 3.45%
5-Year Change -8.77%
10-Year Change -29.78%
Growth Volatility 20.55

CTCBIO Inc - Net Assets Trend (2011–2024)

This chart illustrates how CTCBIO Inc's net assets have evolved over time, based on quarterly financial data. Check tangible equity quality of CTCBIO Inc to evaluate the tangible quality of the company's equity base.

Annual Net Assets for CTCBIO Inc (2011–2024)

The table below shows the annual net assets of CTCBIO Inc from 2011 to 2024. For live valuation and market cap data, see CTCBIO Inc stock valuation.

Year Net Assets Change
2024-12-31 ₩69.62 Billion
≈ $47.18 Million
-7.72%
2023-12-31 ₩75.44 Billion
≈ $51.13 Million
-21.38%
2022-12-31 ₩95.96 Billion
≈ $65.03 Million
+12.88%
2021-12-31 ₩85.01 Billion
≈ $57.61 Million
+11.40%
2020-12-31 ₩76.32 Billion
≈ $51.72 Million
+2.11%
2019-12-31 ₩74.74 Billion
≈ $50.65 Million
-13.97%
2018-12-31 ₩86.87 Billion
≈ $58.87 Million
+17.42%
2017-12-31 ₩73.98 Billion
≈ $50.14 Million
-18.61%
2016-12-31 ₩90.89 Billion
≈ $61.60 Million
-8.32%
2015-12-31 ₩99.14 Billion
≈ $67.19 Million
+15.97%
2014-12-31 ₩85.49 Billion
≈ $57.94 Million
-7.30%
2013-12-31 ₩92.23 Billion
≈ $62.50 Million
+47.80%
2012-12-31 ₩62.40 Billion
≈ $42.29 Million
+39.23%
2011-12-31 ₩44.82 Billion
≈ $30.37 Million
--

Equity Component Analysis

This analysis shows how different components contribute to CTCBIO Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 5538763021000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock ₩12.09 Billion 17.37%
Other Components ₩112.92 Billion 162.19%
Total Equity ₩69.62 Billion 100.00%

CTCBIO Inc Competitors by Market Cap

The table below lists competitors of CTCBIO Inc ranked by their market capitalization.

Company Market Cap
NEORIGIN Co. Ltd
KQ:094860
$46.02 Million
Sekuro Plastik Ambalaj Sanayi AS
IS:SEKUR
$46.02 Million
Shree Rama Newsprint Limited
NSE:RAMANEWS
$46.03 Million
TY Holdings Co Ltd
KO:363280
$46.03 Million
WooriNet Inc
KQ:115440
$45.98 Million
APS Holdings Corporation
KQ:054620
$45.94 Million
Glaston Oyj Abp
HE:GLA1V
$45.94 Million
San Neng Group Holdings Co Ltd
TW:6671
$45.93 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in CTCBIO Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 75,444,321,160 to 69,620,419,960, a change of -5,823,901,200 (-7.7%).
  • Net loss of 5,220,439,230 reduced equity.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ₩-5.22 Billion -7.5%
Other Changes ₩-603.46 Million -0.87%
Total Change ₩- -7.72%

Book Value vs Market Value Analysis

This analysis compares CTCBIO Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.98x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has increased from 0.54x to 0.98x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 ₩5283.66 ₩2840.00 x
2017-12-31 ₩4275.72 ₩2840.00 x
2018-12-31 ₩4563.01 ₩2840.00 x
2019-12-31 ₩3925.70 ₩2840.00 x
2020-12-31 ₩3673.67 ₩2840.00 x
2021-12-31 ₩3640.60 ₩2840.00 x
2022-12-31 ₩4013.72 ₩2840.00 x
2023-12-31 ₩3155.51 ₩2840.00 x
2024-12-31 ₩2911.92 ₩2840.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently CTCBIO Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -7.50%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -3.62%
  • • Asset Turnover: 0.94x
  • • Equity Multiplier: 2.21x
  • Recent ROE (-7.50%) is above the historical average (-7.87%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2012 13.13% 6.31% 1.04x 2.01x ₩1.95 Billion
2013 0.94% 0.70% 0.82x 1.63x ₩-8.35 Billion
2014 -4.10% -2.87% 0.75x 1.90x ₩-12.05 Billion
2015 2.76% 2.30% 0.61x 1.95x ₩-7.17 Billion
2016 -3.01% -2.22% 0.65x 2.08x ₩-11.83 Billion
2017 -27.98% -15.85% 0.68x 2.59x ₩-28.10 Billion
2018 -10.43% -6.55% 0.72x 2.21x ₩-17.75 Billion
2019 -18.38% -10.09% 0.73x 2.50x ₩-21.21 Billion
2020 -25.50% -14.96% 0.73x 2.32x ₩-27.09 Billion
2021 -8.61% -5.22% 0.83x 1.98x ₩-15.82 Billion
2022 7.04% 4.09% 0.88x 1.96x ₩-2.84 Billion
2023 -20.66% -11.31% 0.83x 2.20x ₩-23.13 Billion
2024 -7.50% -3.62% 0.94x 2.21x ₩-12.18 Billion

Industry Comparison

This section compares CTCBIO Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $242,064,566,656
  • Average return on equity (ROE) among peers: -4.26%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
CTCBIO Inc (060590) ₩71.75 Billion 13.13% 1.08x $46.02 Million
ORIENTBIO Inc. (002630) $62.65 Billion -31.14% 0.34x $72.49 Million
Green Cross (005250) $350.47 Billion 6.04% 6.94x $282.59 Million
Green Cross Holdings Preference Shares (005257) $1.67 Trillion 10.22% 0.94x $2.63 Million
Pharmicell (005690) $76.66 Billion 10.78% 0.43x $430.22 Million
GeneOne Life Science Inc (011000) $35.85 Billion -43.51% 0.83x $164.07 Million
HLB Co. Ltd (028300) $19.38 Billion 0.00% 1.48x $2.75 Billion
Mgenplus Co. Ltd. (032790) $46.48 Billion -0.94% 0.63x $15.84 Million
Daesung Microbiological Labs. Co. Ltd (036480) $30.30 Billion 5.14% 0.15x $16.69 Million
Seoulin Bioscience Co.Ltd (038070) $86.05 Billion 0.85% 0.38x $25.87 Million
Hyundai Bioscience Co. Ltd (048410) $39.30 Billion 0.00% 0.56x $395.71 Million

About CTCBIO Inc

KQ:060590 Korea Biotechnology
Market Cap
$46.02 Million
₩67.90 Billion KRW
Market Cap Rank
#22198 Global
#1357 in Korea
Share Price
₩2840.00
Change (1 day)
-3.07%
52-Week Range
₩2770.00 - ₩7450.00
All Time High
₩18000.00
About

CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products. It also provides cardiovascular, gastrointestinal, osteoporosis, antibiotic, smoking cessation, antifungal and antiviral, antiepileptic, allergic rhinitis, dermatology and genito-urinory, allergi… Read more